Please login to the form below
Lundbeck
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lundbeck's 2013 CNS (central nervous system) sales performance.
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others. ... For example, over the last
Lundbeck drops Parkinson’s drug acquired in €905m deal
Disappointment after drug failed in a mid-stage clinical trial. Lundbeck’s acquisition of Pexton Pharma and its Parkinson’s disease candidate foliglurax has ended up being a bust, after the ... Lundbeck paid 100m upfront for Merck Serono spinout
Evoke KYNE appoints global head of digital
She has led marketing and communications activities at the board of director level, as well as in a leadership role at pharma company Lundbeck.
Biohaven gets FDA approval for migraine drug Nurtec ODT
s Emgality (galcanezumab) – as well as Lundbeck’s just-approved intravenous therapy Vyepti (eptinezumab).
Lundbeck gets US approval for migraine drug at heart of Alder takeover
efficacy,” said Deborah Dunsire, chief executive of Lundbeck, which paid almost $2bn for eptinezumab’s developer in a deal that completed in October. ... The slow start could give Lundbeck a chance of catching up in the marketplace.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
